Currently out of the existing stock ratings of Kevin Kedra, 8 are a BUY (44.44%), 8 are a HOLD (44.44%), 2 are a SELL (11.11%).

Kevin Kedra

Work Performance Price Targets & Ratings Chart

Analyst Kevin Kedra works with a stock forecast success ratio of 75% fulfilled within 483.75 days on average.

Kevin Kedra’s has documented 31 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ELAN, Elanco Animal Health at 17-Jun-2021.

Wall Street Analyst Kevin Kedra

Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.

Average potential price target upside

LXRX Lexicon Pharmaceuticals ELAN Elanco Animal Health TTPH Tetraphase Pharmaceuticals PAHC Phibro Animal Health

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

4

$1.91 (91.39%)

8

4 months 7 days ago

4/15 (26.67%)

$2.82 (238.98%)

47

Buy

10

$7.91 (378.47%)

10

1 years 6 months 16 days ago

0/2 (0%)

$7.55 (308.16%)

Buy

2

$-0.09 (-4.31%)

3 years 2 months 21 days ago

2/6 (33.33%)

$-5.91 (-74.72%)

409

Hold

7

$5.91 (542.20%)

3 years 2 months 21 days ago

3/3 (100%)

$1.33 (13.05%)

55

Hold

3 years 3 months 4 days ago

1/1 (100%)

$0.8 (36.36%)

7

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Kevin Kedra?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?